Gallant Therapeutics develops mesenchymal stem cell therapies to treat inflammatory and immune-mediated diseases in pets, targeting the underlying causes rather than just symptoms. Their approach aims to restore healthy tissue and improve mobility, offering new treatment options for conditions like feline chronic gingivostomatitis.
Funding
Funding not disclosed
Founders
Product
Problem
Pets suffering from inflammatory and immune-mediated diseases often have limited treatment options that only address symptoms, leading to pain, reduced mobility, and shortened lifespans. Current treatments often fail to target the underlying causes of these conditions, hindering effective long-term solutions.
Solution
Gallant Therapeutics is developing stem cell therapies designed to treat the root causes of inflammatory and immune-mediated diseases in pets. Their mesenchymal stem cell (MSC) therapies leverage the natural biological mechanisms of stem cells to reduce inflammation, decrease scarring, increase blood supply, and regenerate healthy tissue. This approach aims to restore pets' bodies and improve their overall health and mobility by addressing the underlying disease processes. Gallant is currently focusing on developing a new treatment for feline chronic gingivostomatitis (FCGS), a painful and persistent oral condition in cats.
Target Audience
The primary target audience includes veterinarians and pet owners seeking innovative treatment options for pets suffering from inflammatory and immune-mediated diseases, particularly feline chronic gingivostomatitis (FCGS).
Features
- Mesenchymal stem cell (MSC) therapies targeting the root cause of inflammatory and immune-mediated diseases.
- Focus on reducing inflammation, decreasing scarring, and increasing blood supply.
- Aims to regenerate healthy tissue and restore pets' bodies.
- Development of a new treatment for feline chronic gingivostomatitis (FCGS).
- Off-the-shelf stem cell platform for convenient administration.
- Clinical trials in progress to evaluate the safety and efficacy of their therapies.